^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tybost (cobicistat)

    i
    Other names: GS-9350, JNJ-48763364
    Company:
    Gilead
    Drug class:
    Cytochrome P450 inhibitor
    Related drugs:
    2d
    Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia. (PubMed, Blood Neoplasia)
    Azacitidine/venetoclax is the standard treatment for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy. The potentiated antileukemic activity positions cobicistat as a promising complementary agent in AML therapy. This trial was registered at www.clinicaltrials.gov as NCT06014489.
    Clinical • Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Venclexta (venetoclax) • azacitidine • Tybost (cobicistat)
    1m
    AUGMENT-101: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (clinicaltrials.gov)
    P1/2, N=447, Recruiting, Syndax Pharmaceuticals | N=67 --> 447
    Enrollment change
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2)
    |
    NPM1 mutation • KMT2A rearrangement
    |
    Revuforj (revumenib) • Tybost (cobicistat)
    1m
    KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Helsinki University Central Hospital
    New P1 trial
    |
    Tybost (cobicistat) • Epidiolex (cannabidiol)
    2ms
    KF2024#1-trial: Esketamine Interaction Study (clinicaltrials.gov)
    P1, N=12, Completed, Helsinki University Central Hospital | Not yet recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2025 | Trial primary completion date: Dec 2025 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Tybost (cobicistat)
    4ms
    Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib (clinicaltrials.gov)
    P1, N=15, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: May 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    plixorafenib (FORE-8394) • Tybost (cobicistat)
    5ms
    In silico screening of potential FGF2 inhibitors for cancer therapy. (PubMed, In Silico Pharmacol)
    Molecular docking study showed Elbasvir (1) to exhibit the strongest binding affinity (-8.1 kcal/mol), followed by Velpatasvir (2) (-7.6 kcal/mol), Daclatasvir (3) (-7.5 kcal/mol), Ritonavir (4) (-6.2 kcal/mol), Paliperidone Palmitate (5) (-5.9 kcal/mol), Saralasin (6) (-5.4 kcal/mol), Nystatin (8) (-5.2 kcal/mol), and Cobicistat (-5.1 kcal/mol)...Overall, the study provides mechanistic insights into the molecular interactions between FGF2 and these candidate drugs, highlighting the promising potential of compounds 1-6 and 8 for subsequent in vitro validation in cancer therapeutics. The online version contains supplementary material available at 10.1007/s40203-025-00495-2.
    Journal
    |
    FGFR (Fibroblast Growth Factor Receptor) • FGF2 (Fibroblast Growth Factor 2)
    |
    Tybost (cobicistat) • ritonavir
    6ms
    ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=175, Completed, Constellation Pharmaceuticals | Phase classification: P1b/2 --> P1/2 | Active, not recruiting --> Completed
    Trial completion • Phase classification
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tybost (cobicistat) • lirametostat (CPI-1205)
    8ms
    Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov)
    P=N/A, N=205, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed
    Trial completion
    |
    Tybost (cobicistat)
    11ms
    Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov)
    P=N/A, N=205, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial primary completion date: Apr 2025 --> Jul 2025 | Completed --> Active, not recruiting | Trial completion date: Apr 2025 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tybost (cobicistat)
    11ms
    Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov)
    P=N/A, N=205, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Apr 2025 | Trial primary completion date: Mar 2026 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Tybost (cobicistat)
    1year
    Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov)
    P=N/A, N=205, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | N=325 --> 205
    Enrollment closed • Enrollment change
    |
    Tybost (cobicistat)
    1year
    Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B). (PubMed, Contemp Clin Trials Commun)
    A total of 142 patients (128 patients with BRCA+, high-grade, FIGO III/IV ovarian cancer who receive olaparib as maintenance therapy; 14 patients with other approved indications for olaparib) who start olaparib treatment in line with the drug label will be randomized between the standard monotherapy of olaparib 300 mg twice daily (BID) and the boosted therapy of olaparib 100 mg BID with cobicistat 150 mg BID. Moreover, the lower costs related to the boosted therapy contribute to a durable and accessible anticancer treatment for all patients. The PROACTIVE study has been published at ClinicalTrials.gov under NCT05078671 on October 14, 2021 and at EudraCT under 2021-004032-28 on August 24, 2021.
    PK/PD data • Journal • Head-to-Head
    |
    BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • Tybost (cobicistat)